ArticleBMC nephrology2025
The neutrophil-to-monocyte ratio: a superior inflammatory marker predicting poor prognosis in IgA nephropathy.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveImmunoglobulin A nephropathy (IgAN) is a chronic immune-mediated inflammatory disorder, and a substantial body of research indicates that the activation of inflammatory responses plays a pivotal role in its onset and progression. We conducted a comprehensive assessment of the influence of systemic inflammatory markers, specifically the neutrophil-to-monocyte ratio (NMR), lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), platelet-to-albumin ratio (PAR), and the systemic immune-inflammation (SII), on the phenotypic manifestations and disease progression of IgAN.
methodsA retrospective cohort study was conducted, involving 559 patients who underwent regular follow-up evaluations spanning a minimum of one year. The utility of these inflammatory indicators in predicting IgAN progression was quantified using the area under the receiver operating characteristic curve (AUROC). The kidney progression event was defined as a 30% estimated glomerular filtration rate (eGFR) decline or end-stage kidney disease or death. A prognostic model was developed using Cox proportional hazards regression. Circulating levels of galactose-deficient IgA1 (Gd-IgA1), factor B, and mannose-binding lectin (MBL) were quantitatively determined through enzyme-linked immunosorbent assay (ELISA).
resultsAmong the investigated markers, NLR demonstrated the highest prognostic utility, with an AUROC of 0.622 (p < 0.001) at a cutoff value of 2.11. NMR and SII followed closely, exhibiting AUROCs of 0.611 (p < 0.001) and 0.581 (p = 0.006) respectively, at their respective cutoff points of 8.25 and 560.11. Conversely, LMR, PLR, and PAR yielded AUROCs below the statistical significance threshold (0.473, 0.532, and 0.556, respectively; all p > 0.05). Univariate Cox regression analysis revealed that elevated neutrophil counts, NMR, NLR, SII, urinary leukocyte levels, and severe Oxford C score were predictive of IgAN progression. Notably, NMR emerged as an independent risk factor for adverse renal outcomes in IgAN patients, even after adjusting for established risk factors, whereas NLR and SII lost statistical significance. Patients with high NMR displayed more pronounced clinical-pathological features and elevated Gd-IgA1 and factor B levels compared to those with low NMR, whereas no such correlation was observed between Gd-IgA1 and either NLR or SII.
conclusionsOur findings highlight the crucial role of NMR as an independent predictor of disease progression in IgAN, underscoring its utility in risk stratification for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.